Tandem Diabetes Care (NSDQ:TNDM) announced today that Health Canada has approved its t:slim X2 insulin pump with Control-IQ technology.
The news comes nearly a year after the U.S. launch of the t:slim X2 with Control-IQ. All in-warranty t:slim X2 pump users in Canada will be able to add Control-IQ technology to their existing pump via a remote software update — starting in March 2021, and new t:slim X2 insulin pumps with Control-IQ tech will start shipping in Canada in Q1 2021.
The Control-IQ technology — which integrates with Dexcom G6 continuous glucose monitoring — requires no fingersticks for calibration or diabetes treatment decisions. The Control-IQ tech uses CGM readings to predict glucose values 30 minutes ahead and can increase, decrease, or stop basal insulin delivery to help keep glucose in-range (3.9-10 mmol/L). The technology can automatically correct boluses, and there are optional sleep and exercise settings.
“The t:slim X2 insulin pump with Control-IQ technology is the most advanced automated insulin dosing system available in the world and is a testament to our commitment to improving the lives of people with diabetes,” Tandem CEO John Sheridan said in a news release. “We are thrilled to be able to bring the benefits of this advanced hybrid closed-loop system to the Canadian diabetes community.”
